A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson’s disease Mario van der Stelt * , 1 , 2 , Susan H. Fox † , 1 , Michael Hill ‡ , 3 , Alan R. Crossman ‡ , Stefania Petrosino * , Vincenzo Di Marzo * ,4 and Jonathan M. Brotchie § ,4 * Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli (NA), Italy; † Movement Disorders Clinic, Toronto Western Hospital, Toronto, Canada; ‡ Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester UK; and § Toronto Western Research Institute, Toronto Western Hospital, Toronto, Canada 4 Correspondence: J.M.B., Toronto Western Research Institute, MC 11-419, Toronto Western Hospital, 399, Bathurst St, Toronto ON, Canada M5T 2S8. E-mail: Brotchie@uhnres.utoronto.ca ; V.D.M., Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078, Pozzuoli (NA) Italy. E-mail: vdimarzo@icmib.na.cnr.it <h3>SPECIFIC AIMS</h3> The aim of the present study was to assess systematically in nonhuman primates the role of endocannabinoid stimulation of cannabinoid CB1 receptors in the generation of symptoms of parkinsonism and L-DOPA-induced dyskinesia (LID), the major complication of treatments for PD and the major
/lp/fed-of-american-socs-for-experimental-biology/a-role-for-endocannabinoids-in-the-generation-of-parkinsonism-and-xjF4iC2QEM